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Abstract
Instrumental variable (IV) methods are widely used for estimating average treat-
ment effects in the presence of unmeasured confounders. However, the capability of
existing IV procedures, and most notably the two-stage residual inclusion (2SRI) pro-
cedure recommended for use in nonlinear contexts, to account for unmeasured con-
founders in the Cox proportional hazard model is unclear. We show that instrumenting
an endogenous treatment induces an unmeasured covariate, referred to as an individual
frailty in survival analysis parlance, which if not accounted for leads to bias. We pro-
pose a new procedure that augments 2SRI with an individual frailty and prove that it
is consistent under certain conditions. The finite sample-size behavior is studied across
a broad set of conditions via Monte Carlo simulations. Finally, the proposed method-
ology is used to estimate the average effect of carotid endarterectomy versus carotid
artery stenting on the mortality of patients suffering from carotid artery disease. Re-
sults suggest that the 2SRI-frailty estimator generally reduces the bias of both point
and interval estimators compared to traditional 2SRI.
Keywords: Two-stage residual inclusion; Individual frailty effect; Unmeasured con-
founding.
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Ever since Cox’s seminal paper in 1972 (Cox, 1972), the Cox proportional hazards
models has become one of the most widely used statistical models due to the ubiquity in
medicine of time-to-event outcomes subject to censoring. Although the Cox model was
traditionally applied to analyze small data sets from randomized clinical trials (RCT),
the increasing cost of RCTs and increasing availability of observational data has led to
increased utilization of the Cox model in non-randomized settings. A clever observational
study, perhaps in conjunction with a small RCT, can overcome the necessity for a large and
highly expensive RCT. Registries containing the procedures and outcomes of all patients
with a particular diagnosis (e.g., the Surveillance, Epidemiology, and End Results (SEER)
program of the National Cancer Institute, https://seer.cancer.gov/about/), or that
have undergone a certain procedure (e.g., the Vascular Quality Initiative, VQI, registry,
http://www.vascularqualityinitiative.org/), are typically designed to measure all
known risk factors and so yield high quality observational data. Nonetheless, unmeasured
confounding is a concern whenever randomization is lacking. Instrumental variable (IV)
methods (Angrist et al., 1996) allow causal interpretations from an analysis of observation
data. They may also be applied to RCTs with imperfect compliance in which the objective
is to estimate the effect of treatment received (the average treatment effect of the treated)
rather than just intention-to-treat. However, even if a valid IV is available (e.g. treatment
assigment in a RCT), an unresolved question in statistics and econometrics is the best way
of using an IV with the Cox model. In this paper we seek to answer this question.
There are many real-world applications in which hazard ratio (HR) estimates from RCT-
comparisons and Cox models estimated on observational data differ even after controlling
for detailed clinical information on patients, suggesting the need to develop IV procedures
for Cox models. For example, large differences were observed in the HR of death for carotid
endarterectomy versus carotid artery stenting estimated using the Cox model adjusted for
covariates in the VQI and the results of recent randomized clinical trials (Rosenfield et al.,
2016; Brott et al., 2016). The VQI analysis finds an estimated hazard ratio (HR) of 0.693
(95% confidence interval: (0.633; 0.760)), implying longer survival times under endarterec-
tomy, whereas both clinical trial found almost null effects (approximate HR of 0.97, 95%
CI (0.93; 1.02) and 0.91 (0.69; 1.20), respectively). The profound difference in these results
may be due unmeasured confounders that have a strong effect on the procedure a VQI
patient receives and their subsequent survival time. Therefore, the development of an IV
procedure for survival time data that yields RCT-like estimates for a more general VQI
population is highly desired.
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In the context of structural linear equations, the two-stage least squares estimator, 2SLS,
was introduced in econometrics in the 1950s by various authors (see Anderson (2005) and
references therein). IV procedures have subsequently been used to estimate causal effects
from observational studies (Martens et al., 2006) in statistics, biomedicine, and many other
applied research fields. The Directed Acyclic Graph (DAG) (Pearl, 1995) in Figure 1
presents the basic IV identification strategy of conditioning on the IV W instead of the
treatment X in order to block the flow of association from the unmeasured confounder U
to the outcome Y through X, thereby identifying the causal effect of X on the outcome
Y .
Conventional instrumental variable methods can produce substantial estimation bias
when the true underlying models are nonlinear (Terza et al., 2008). The direct nonlinear
generalization to 2SLS is the two-stage predictor substitution, 2SPS, procedure (Greene and
Zhang, 2003). In the first stage, the relationship between the IV, W , and the exposure, X,
is estimated by any consistent estimation technique. Then, the resulting fitted exposure
status replaces the real observed exposure in the outcome model.
Alternatively, Hausman (1978) proposed the two-stage residual inclusion, 2SRI, or con-
trol function estimator. The 2SRI computes the expected exposure as for 2SPS but for the
second-stage augments the target model with the residuals from the first-stage. The first
and second stage models can be linear or nonlinear. Although there exists some debate
about the relative performance of the 2SPS and 2SRI procedures, 2SRI is generally consid-
ered to have theoretical and practical advantages over 2SPS (Terza et al., 2008; Normand
et al., 2011). Cai et al. (2011) compared the bias of the 2SPS and 2SRI procedures at esti-
Figure 1: DAG with unmeasured confounder U , treatment X, and outcome Y . The IV W
is related with Y only through X.
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mating the odds ratio among compliers under the principal stratification framework. They
found that 2SRI is asymptotically unbiased in the absence of unmeasured confounding but
bias increasingly occurs with the magnitude of unmeasured confounding while 2SPS was
always biased. See Klungel et al. (2015) for an extensive review of different IV procedures
for both linear and nonlinear contexts.
The estimation of treatment effects by IVs for time-to-event outcomes has received at-
tention recently. The challenge is the presence of right censoring and non-linearity. Due to
the presence of additive effects and an explicit error term, accelerated failure time models
(Robins and Tsiatis, 1991) and additive hazard models (see, for instance, Li et al. (2015),
Tchetgen Tchetgen et al. (2015) and references therein) are the most common frameworks.
However, in biomedical and epidemiological research proportional hazard models are over-
whelmingly used to analyze time-to-event outcomes.
Most practitioners are familiar with Cox’s proportional hazard model (Cox, 1972) and
interpreting research results in terms of hazard ratio. An IV estimator of the hazard ratio
has been proposed that assumes that the omitted covariates have an additive effect on the
hazard (MacKenzie et al., 2014). A consistent estimator of the hazard ratio has been de-
rived for the setting of a binary instrument (e.g. randomization), (MacKenzie et al., 2016).
However, from a causal standpoint estimating the hazard ratio is problematic (Herna´n,
2010). Because the hazard function is the instantaneous change in the survival probabil-
ity, survival status Yt0 just prior the instantaneous time period is conditioned on thereby
inducing an association between treatment and any unmeasured predictor of survival (Fig-
ure 2), a phenomena known as collider bias. Intuitively, the problem is that even if X is
independent of U at time 0, it is not independent at any time t > 0 because selection out
of the sample depends on U .
A consequence of collider bias is that if the path U → X exists then blocking it using
an IV is not sufficient to identifying the causal estimate for the HR of X on Yt, bringing
the performance of IV methodology at estimating HRs into question. This is seen from
evaluations of the bias of both the 2SPS and the 2SRI procedures on causal hazard ratio
estimation under Weibull models (Cai et al., 2011) and in other contexts (Wan et al., 2015),
which found that no procedure consistently performed the best and that the bias of the IV
estimator of the causal hazard ratio depended on the form of the unmeasured confounder,
and magnitude of its effect, and the data structure.
Even if U does not have a causal effect on X, it is known that under the proportional
hazard assumption the true effect of measured covariates on the hazard-ratio is underesti-
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mated if U is ignored (Chamberlain, 1985; Gail et al., 1984). Therefore, in survival time
models, omitted predictors unrelated with treatment assignment should be accounted for
to avoid misspecification (Schmoor and Schumacher, 1997), a contrast to a linear regression
model where an explicit error term would absorb U . Because omitted predictors of survival
that are unrelated with any of the measured predictors manifest as frailties, the addition
of an individual frailty (Wienke, 2010) appears to be a possible remedy.
The crux of the research in this paper rests on the observation that if (i) a continuously
valued exposure, X, is related to an instrumental variable W and a covariate U by the linear
model, X = αW ·W+αU ·U+, and (ii) the effects of X and U on a time-to-event, Y , satisfies
the Cox model, P{Y ≥ t|X = x, U = u} = exp{−Λ0(t) exp{βX · x + βU · u}}, then the
conditional distribution of the time-to-event given the exposure, X, and R = X − αW ·W
satisfies the Cox model with frailty term: P{Y ≥ t|X = x,R = r} = P{Y ≥ t|X =
x, αU · U +  = r} = P{Y ≥ t|X = x, U = α−1U · (r − )} = E[P{Y ≥ t|X = x, U =
α−1U ·(r−)}] = E[exp{−Λ(t)·z ·exp{βX ·x+βU ·α−1U ·r}}] where z = exp{−βU ·α−1U ·} is the
frailty term. The above expectation has the form of a Cox model with a frailty, suggesting
that 2SRI will work in the context of Cox’s model if the second stage is implemented
with a frailty. Specifically, the procedure requires that the distribution specified for the
frailty matches the distribution of the noise term in the linear model of X given W and
U . This strategy assumes that αU 6= 0, the omitted covariates are related with treatment
assignment, and that αW is known thereby motivating evaluation of what happens when
αW (and hence X) is estimated, when X is binary, and when the wrong frailty distribution
Figure 2: Directed acyclic graph, DAG, showing the unmeasured confounder U , treatment
X, and the time-to-event outcome Y at t0 and t = t0 +  where  represents an arbitrarily
small amount of time. The independent variable W , related with Yt0 and Yt only through
X is an instrumental variable.
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is assumed.
The novel contributions of this paper are to: (i) confirm the above reasoning that 2SRI
applied to the Cox model induces a frailty, (ii) derive a 2SRI algorithm with an individual
frailty term in the second stage estimation, (iii) explore the performance of the procedure
both when X is binary (as opposed to continuous), and (iv) evaluate the robustness of
the procedure to misspecification of the frailty distribution. The remainder of the paper is
structured as follows. The notation and assumed underlying model are defined in Section
2. Theoretical justification of the 2SRI-frailty procedure is provided in Section 3. Section
4 evaluates the operating characteristics of the new 2SRI-frailty procedure using Monte
Carlo simulations. We consider the common situation in which we have a binary treatment
with continuous IV and continuous measured and unmeasured covariates. We first consider
the case where the exact same unmeasured predictors are present in both the treatment
selection and the survival time models. We then consider the more realistic scenario where
there are related but different unmeasured confounders in the survival and the treatment
selection models, in which the first scenario is a special case. In Section 5, the proposed
methodology is applied to an observational study where the goal is to estimate the average
effect on mortality of the treatment (carotid endarterectomy (CEA) versus carotid artery
stenting (CAS)) received by patients suffering from carotid artery disease. The paper
concludes in Section 6.
1 Notation and models
Conventionally, the right-censored framework assumes the sample {(ti, δi)}Ni=1, where ti =
min{yi, ci} and δi = I(−∞,ci](yi) (IA(x) stands for the usual indicator function, taking value
1 if x ∈ A and 0 otherwise), and ci and yi are the censoring and the survival times for the
ith subject (1 ≤ i ≤ N), respectively. Let SY (·) = P{Y > ·} denote the survival function
of Y . The Cox proportional hazard model is given by
d[logSY (t|X,Z,U)] = −λ0(t) · exp{β0 + βX ·X + βtZ ·Z + βtU ·U}, (1)
where λ0(·) is the baseline hazard function, X is a random variable representing the study
treatment, Z is a random vector of exogenous measured predictors and U is a random
vector of unmeasured predictors.
The goal is to estimate the value of βX ; that is, the average change in the risk of an
individual caused by a change in the received treatment.
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We assume that an individual’s received treatment is the result of the selective process
depicted by the equation,
X = α0 +α
t
W ·W +αtZ ·Z +αtV · V + , (2)
with W a measured random vector and V a random vector of unmeasured variables that
may be correlated with unmeasured variables in U . The term  is an independent random
component representing the difference between the variable X and the predicted values
obtained in the linear model. Note that the uncontrolled relationship between the unmea-
sured covariates affecting survival and treatment selection operate through the relationship
between U and V and/or Z. If V ⊥⊥ U , the survival model just contains unmeasured
covariates, U , that are not unmeasured confounders.
If the random vector W satisfies:
C1. W 6⊥⊥ (X|Z, U, V ),
C2. W ⊥⊥ (Y |X, Z, U) (exclusion restriction assumption),
C3. W ⊥⊥ (V, U |Z) (randomization assumption),
then W can be considered an instrumental variable. The strength of the instrument is
reflects the strength of the relationship between W and X. In a randomized trial with
perfect compliance, assigned treatment is a perfect instrument. Assumptions C1, C2 and
C3 can be reformulated and combined with the stable unit treatment value assumption,
SUTVA, and the monotonicity assumption (Herna´n and Robins, 2006) between the treat-
ment to complete the conditions under which the IV W identifies the causal effect of X
non-parametrically (i.e., without relying on (1) and (2)). Common instruments include prior
institutional affinity for using a particular procedure, geographic region of residence, an in-
dividual’s differential access to certain treatments, and an individuals genes (aka Mendelian
randomization, Thanasassoulis and O’Donnell (2009)).
2 Proposed methodology
The proposed methodology considers a standard first stage in which the relationship among
the treatment, X, the instrument variable, W , and the measured confounding, Z, is es-
timated by any consistent method. We use simple linear regression models with standard
least squares estimation but more flexible procedures could also be implemented. The first
stage procedure is:
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Step 1. From the data, estimate the parameters to obtain the predicted values
Xˆ = αˆ0 + αˆ
t
W ·W + αˆtZ ·Z.
Then, compute the residuals, Rˆ = X − Xˆ.
It is worth noting that, under model (1) and assuming Z ⊥⊥ V , Rˆ is a consistent
estimator of [αtV ·V + ]. If Z 6⊥⊥ U , Rˆ estimates [(αZ − αˆtZ) ·Z+αtV ·V + ]. Almost sure
convergence of αˆZ to αZ is not guaranteed. The residual Rˆ contains all the information
about the unmeasured vector U related with the treatment assignment and unrelated with
Z; that is, all the available information about unmeasured confounding is contained in the
residuals provided by the model (1). However, Rˆ also contains white noise pertaining to
idiosyncratic or purely random factors affecting an individual’s treatment selection, which
corresponds to the difference between the unmeasured covariates in the two models, V and
U , and to the independent random term  in model (2). We conjecture that the component
of Rˆ due to white noise can be handled by specifying an individual frailty in the outcome
model in order to allow Rˆ to more fully be able to perform its intended task of controlling
for U . The proposed second stage is:
Step 2. Estimate the Cox proportional hazard regression with individual frailty:
d[log SˆY (t|X,Z, Rˆ, F )] = −z · λˆ0(t) · exp{βˆ∗0 + βˆIVX ·X + βˆ
∗ t
Z ·Z + βˆRˆ · Rˆ},
where z = exp{F} is the individual frailty term. A distribution should be specified
for F (e.g., log-Gaussian, Gamma). The parameter estimate of βX that results from
this procedure is denoted βˆIVX .
Standard algorithms for estimating Cox models with frailties may be used to imple-
ment the procedure. For example, Therneau et al. (2003) proved that maximum likelihood
estimation for the Cox model with a Gamma frailty can be accomplished using a general
penalized routine, and Ripatti and Palmgren (2000) derived a similar argument for the Cox
model with a Gaussian frailty.
2.1 Asymptotic properties of βˆIVX
We derive the asymptotic distribution of the 2SRI-frailty estimator βˆIVX for the case in
which U = V . If U 6= V a similar derivation can be performed by decomposing U and
V into common and orthogonal terms and making standard reliability assumptions on the
distributions of these terms.
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By adapting the convergence results for Cox’s partial likelihood (see, for instance, The-
orem 5.3.1 in Kalbfleisch and Prentice (2002)) we obtain the following convergence results.
Theorem. Assume the causal models
d[logSY (t|X,Z,U)] = −λ0(t) · exp{β0 + βX ·X + βZ · Z + βU · U}, (3)
X = α0 + αW ·W + αZ · Z + αU · U + , (4)
with the random variables X (the treatment), Z (measured covariate) and U (unmeasured
covariate). In addition, assume that U is normally distributed, that  is independently
normally distributed random noise, and that W (the instrument) is a random variable
satisfying C1-C3. Then, if the censoring time, C, satisfies C ⊥⊥ (Y |X, Z, U, W ), we have
the weak convergence,
√
n ·
{
βˆIVX − βX
} L−→ N (0, σIVX ) , (5)
where
(
σIVX
)2
= n·V[βˆIVX ] (V stands for the variance operator) can be consistently estimated
from the survival and at-risk counting processes.
Proof. In absence of the frailty term, it is well-known that the estimator of β that maximizes
the Cox-model partial likelihood function obeys the asymptotic law
√
n · {βˆ − β} L−→ Np
(
0, I−1(β)
)
, (6)
where β = {β∗0 , βX , β∗Z}, and I(β) is the p × p (p stands for dimension of the vector β)
information matrix Kalbfleisch and Prentice (2002), which can be consistently estimated
by I(βˆ).
In the presence of an individual frailty, different estimation methods have been pro-
posed. Particularly, Ripatti and Palmgren (2000) and Vaida and Xu (2000) studied the
case of multiplicative log-normal distributed frailties. The proposed methodology obtains
maximun-likelihood estimates of the regression parameters, the variance components and
the baseline hazard, as well as empirical Bayes estimates of the random effects (frailties).
Therefore, it suffices to prove that the second stage of our proposed 2SRI-frailty procedure
is a Cox proportional hazard model with a gaussian frailty term in which the coefficient
related with the treatment is unchanged from the original model (i.e., βX).
Given the causal equation in (4) and C1 − C3, S1 yields
Rˆ = (α0 − αˆ0) + (αZ − αˆZ) · Z + αU · U + +O(n−1/2).
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Hence, αU ·U = Rˆ−{(α0− αˆ0) + (αZ − αˆZ) ·Z + +O(n−1/2)}. If αU = 0, the linear part
of the model in (3) can be rewritten as,
L =β0 + βX ·X + βZ · Z + βU · U
=β∗0 + βX ·X + β∗Z · Z + Rˆ+ F,
where β∗0 = β0 − (α0 − αˆ0) + βU · E[U ], β∗Z = βZ − (αZ − αˆZ) and F = βU · (U − E[U ]) +
+O(n−1/2). Due to  and U being independent normally distributed variables, F is also
asymptotically independent and normally distributed. If αU 6= 0, then
L = β∗0 + βX ·X + β∗Z · Z + βRˆ · Rˆ+ F,
with βRˆ = βU/αU , and where, in this case, β
∗
0 = β0−βRˆ ·(α0−αˆ0), β∗Z = βZ−βRˆ ·(αZ−αˆZ)
and F = βRˆ ·  + O(n−1/2). Therefore, F is asymptotically independent and normally
distributed due to  being independent and normally distributed. Hence, the survival
model is given by
d[logSY (t|X,Z,U)] = −λ0(t) · z · exp{β∗0 + βX ·X + β∗Z · Z + βRˆ · Rˆ},
which has the form of a Cox proportional hazards model with frailty z = exp{F}. Therefore,
if βˆ = {βˆ∗0 , βˆIVX , βˆ∗Z} is the estimator resulting from step S2, invoking the censoring time
assumptions and using the convergence of the partial maximum-likelihood method given a
consistent method of estimating the product of the baseline risk and the frailty (Ripatti
and Palmgren, 2000; Vaida and Xu, 2000), it follows that
√
n ·
{
βˆIVX − βX
} L−→n N (0, σIVX ) , (7)
with (σIVX )
2 the component in the matrix I−1(β) corresponding to βX . 
Remark. Normality of U is required only when αU = 0. In this case, the survival
model does not contain unmeasured confounders, just unmeasured covariates. Such white
noise can be omitted in standard linear models, but not in Cox regression models where
it underestimates the treatment effect. The key point is that the first stage residual adds
individual variability (a frailty) in the Cox model estimated in the second-stage.
3 Monte Carlo Simulation Study
To evaluate the behavior of the proposed methodology in finite samples, we conducted a
range of Monte Carlo simulations. We found that, beyond the expected effect on precision of
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estimation, neither the baseline shape of the survival times nor the censorship distribution
have any meaningful effect on the observed results. Therefore, we only show results when
the baseline survival times follow a Weibull distribution with shape parameter two and scale
parameters coherent with the proportional hazard assumption; that is, the scale parameter
equates to exp{1 +βX · (X − X¯) +Z+βU ·U}. Here βX is the target. We subtract X¯ from
X, as opposed to drawing X from a distribution with mean 0, to ensure that we obtain
realistic survival times with binary X without needing to alter the intercept. Z and U
denote the measured and unmeasured confounders, respectively. Both the measured (Z)
and unmeasured (U) covariates follow independent standard normal distributions, N0,1.
Censoring was independently drawn from a Weibull distribution such that the expected
censorship was 20%. Treatment assignment is based on the linear equation X∗ = 1 +W +
Z + αV · V + , where W is the instrument, V is the unmeasured covariate, and  is the
random noise. We set X = X∗ for a continuous exposure and X = I(X∗ ≥ 0) for a binary
exposure. All of W , V , and  are drawn from independent standard-normal distributions.
Notice that, after fixing the rest of the parameters, increasing αV yields an instrumental
variable of lesser quality. Sample size was fixed at N = 500.
3.1 All Omitted Covariation is Unmeasured Confounding
We first suppose X = X∗, U = V and  follow possibly correlated standard normal dis-
tributions. That is, the endogenous variable is continuous and there are no unmeasured
predictors of survival time unrelated with treatment selection (i.e., while the true Cox model
of the survival times may include a shared covariate with the treatment selection process,
it does not include a frailty).
Figure 3 shows the median of the bias observed in 2000 Monte Carlo iterations for a
stronger, αV = 1, and weaker, αV = 2, instrument. The Naive Cox model, which ignores
the presence of omitted covariates, only performed well for βU = 0 (there are no omitted
covariates and the Cox model is correct). The proposed algorithm, 2SRI-frailty (2SRI-F),
reduced bias the most when the omitted covariates had strong effects. When the presence
of unmeasured confounding was weaker (βU close to zero), and when there was no effect
of the treatment, βX = 0, both 2SRI and 2SRI-F obtained similar results. Median-bias
appeared to be invariant to the strength of the instrument.
Table 1 reports the coverage of the 95% confidence intervals computed from the standard
asymptotic variance obtained from the second-stage Cox regression models of the respective
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procedures, ignoring the first stage variability.The proposed algorithm achieved coverage
close to the nominal level in all cases, suggesting that it will be able to be implemented
easily in practice. In contrast, the coverage of the naive Cox methods and the basic 2SRI
algorithm was poor. As expected, the naive method performed correctly for βU = 0, the
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Figure 3: Median bias for Weibull(exp{1 + βX · X + Z + βU · U}, 2) times and X =
X∗ = 1 + Z +W + αV · U + , where Z, U , W and  follow independent standard normal
distributions. Gray-dotted, naive Cox model (omitted covariate is ignored); black-dashed
2SRI, procedure; blue-continuous, 2SRI-F (2SRI plus Gaussian frailty). Continuous black
thin line stands for the zero-bias situation.
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Table 1: Observed coverage of 95% confidence intervals for the Cox model treatment effect
covariate, Naive, 2SRI algorithm and the proposed 2SRI algorithm with gaussian individual
frailty (2SRI-F).
αUX = 1 αUX = 2
eβU eβX Naive 2SRI 2SRI-F Naive 2SRI 2SRI-F
1/2 1/2 0.466 0.671 0.871 0.019 0.867 0.891
1 0.000 0.931 0.931 0.000 0.917 0.922
2 0.000 0.670 0.884 0.000 0.868 0.898
1 1/2 0.952 0.951 0.912 0.952 0.851 0.912
1 0.940 0.948 0.949 0.940 0.948 0.949
2 0.943 0.947 0.915 0.943 0.947 0.915
2 1/2 0.000 0.617 0.857 0.000 0.861 0.874
1 0.000 0.935 0.940 0.000 0.902 0.907
2 0.396 0.685 0.992 0.012 0.878 0.898
case when the model is correct. As is well-known, two-stage instrumental variable methods
lead to estimators (βˆIVX ) with the degree of variance inflation depending on the strength of
the instrumental variable. We found that the length of the 95% confidence intervals ranged
between 0.09 and 0.17 for the naive models, between 0.20 and 0.23 for 2SRI and between
0.21 and 0.26 for the proposed 2SRI-F method, respectively, for both αV = 1 and αV = 2.
The fact that the 2SRI-F procedure imposes a greater amount of inflation compared to
2SRI is helpful in terms of its ability to maintain the nominal level of coverage. Crucially,
it appears that the 2SRI-F’s assumption of the distribution of the frailty is helpful in
addressing bias and does not suffer from the excessive and inappropriate gains in precision
that accompany many procedures with parametric components.
3.2 Omitted Covariation is a Mixture of Unmeasured Confounding and
a Pure Individual Frailty
Figure 4 depicts the observed median bias for the previous scenario for αV = 1 and
cor(U, V ) = ρ. Note that ρ = 0 implies that the survival model does not contain un-
measured confounders, only unmeasured covariates, while ρ = ±1 implies that all omitted
covariation manifests as unmeasured confounding (i.e., is also related to treatment assign-
ment). In the ρ = 0 case, it is reassuring that the 2SRI and the 2SRI-F procedures perform
nearly as well as the naive Cox regression model, the true model in this scenario. The
13
advantage of using 2SRI-F versus 2SRI was larger for ρ close to zero, which makes sense as
the pure frailty variation is at its maximum, whereas at values close to ±1 the frailty has
all but disappeared.
In order to check the robustness of the recommended gaussian frailty with respect to the
unmeasured covariates distribution, we study the case where the unmeasured covariates, U
and V , are not normally distributed. In particular, we considered the following scenarios:
M-I. U =
√
a · γ1 +
√
(1− a) · γ2; V =
√
a · γ1 +
√
(1− a) · γ3.
M-II. U =
√
a · γ1 +
√
(1− a) · η1; V =
√
a · γ1 +
√
(1− a) · η2.
M-III. U =
√
a · η1 +
√
(1− a) · η2; V =
√
a · η1 +
√
(1− a) · η3.
M-IV. U =
√
a · η1 +
√
(1− a) · γ2; V =
√
a · η1 +
√
(1− a) · γ3.
where γ1, γ2 and γ3 follow independent centered Gamma(1,1) and η1, η2 and η3 follow
independent standard normal distribution. Note that parameter a determines both the
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Figure 4: Median bias for Weibull(exp{1 + βX · X + Z + βU · U}, 2) times and X =
1 + Z + W + U + , Z, U , W and  follow standard normal distributions. Correlation
between U and V is ρ. Gray-dotted, naive Cox model with a Gaussian frailty term (omitted
covariate is ignored but a Gaussian frailty is included in the model); black-dashed 2SRI,
procedure; blue, 2SRI-F (2SRI plus Gaussian frailty). Continuous black thin line stands
for the zero-bias situation.
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distribution and the relationship between U and V and it is chosen in order to keep constant
the marginal variance. Figure 5 shows the median of the bias of 2SRI-F algorithm observed
in 2000 Monte Carlo iterations under the previous models with a ∈ [0, 1]. Results suggest
minimal impact of the unmeasured covariates distribution. As expected, when the frailty
has the assumed distribution the bias is smaller but, crucially, observed biases were always
smaller than under the 2SRI procedure.
3.3 Nonlinear Treatment Selection Model: Binary Exposure
The second scenario supposes X = I[0,∞)(X∗), a binary exposure. Because other values of
ρ produced similar results, we only report results for which the correlation between U and
V was fixed at ρ = 1/2.
Figure 6 depicts the median bias over 2000 Monte Carlo iterations when βX was directly
estimated from Cox regression with Gaussian frailty, (due to the presence of an unmeasured
covariate unrelated with treatment assignment, this model is the correct model in the
absence of unmeasured confounding), the 2SRI procedure, and 2SRI-F. A stronger (αV = 1)
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Figure 5: Median bias for Weibull(exp{1 + βX · X + Z + βU · U}, 2) times and X =
1 + Z + W + U + , Z and  follow standard normal distributions and U and V following
previous models always using the 2SRI-F algorithm. Continuous black thin line stands for
the zero-bias situation.
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Table 2: Observed coverage of 95% confidence intervals for the Cox model treatment effect
covariate, Naive, 2SRI algorithm and the proposed 2SRI algorithm with gaussian individual
frailty (2SRI-F).
αUX = 1 αUX = 2
eβU eβX Naive-F 2RSI 2RSI-F Naive-F 2RSI 2RSI-F
1/2 1/2 0.325 0.885 0.943 0.102 0.916 0.947
1 0.189 0.936 0.944 0.041 0.944 0.947
2 0.158 0.885 0.938 0.037 0.925 0.946
1 1/2 0.941 0.954 0.949 0.936 0.944 0.943
1 0.946 0.943 0.947 0.950 0.949 0.947
2 0.936 0.946 0.944 0.939 0.905 0.947
2 1/2 0.158 0.883 0.936 0.036 0.943 0.942
1 0.212 0.940 0.946 0.038 0.927 0.942
2 0.321 0.880 0.933 0.099 0.914 0.948
and a weaker (αV = 2) scenario was considered for the instrument. Not surprisingly,
ignoring the presence of the frailty and estimating a standard Cox regression model results
in larger bias, even in the absence of an unmeasured confounder. The 2SRI algorithm
helps us to control just the part of the bias related with the treatment assignment but
also fails to handle the frailty and its performance suffers as a result. The naive Cox
model with a frailty performs much better than both the naive Cox model with no frailty
and 2SRI, implying that accounting for the frailty may be more important than dealing
with unmeasured confounding. However, the proposed 2SRI-F methodology produces a
yet further reduction in bias, to close to zero in all scenarios, which we conjecture is due
to separating the idiosyncratic and confounding effects of U . These results reveal that
there is clear benefit to be gained in practice from using 2SRI-F as an IV procedure for
time-to-event data.
Both the 2SRI and the proposed algorithms achieved coverage close to the nominal level
in all scenarios; the naive Cox model with Gaussian frailty (Naive-F) understandably yields
good results only when βU = 0 (Table 2). As expected, the strength of the instrument affects
the confidence interval widths. The width of the 95% confidence interval ranged between
0.44 and 0.57 for the Naive-F models. Under αV = 1 interval estimatior width ranged
between 0.86 and 0.88 and between 0.91 and 1.07 for the 2SRI and 2SRI-F, respectively.
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Figure 6: Median bias assuming Weibull(exp{1+βX ·X+Z+βU ·U}, 2) survival times and
X∗ = 1+Z+W+αV ·U+, with X = I[1,∞)(X∗), Z, U , W and  following standard normal
distributions. Correlation between U and V is 1/2. Legend: Gray-dotted, naive Cox model
with Gaussian frailty (omitted covariate is ignored but a Gaussian frailty is included); black-
dashed 2SRI, procedure; blue, 2SRI-F (2SRI plus Gaussian frailty). Continuous black thin
line stands for the zero-bias situation.
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For αV = 2 the widths ranged between 1.23 and 1.31 and between 1.30 and 1.53 for 2SRI and
2SRI-F, respectively. These results are consistent with the results for continuous exposures;
the variance inflation under the 2SRI-F procedure exceeds that under 2SRI which in-turn
exceeds that under Naive-F.
4 Real-world application: The Vascular Quality Initiative
dataset
We apply 2SRI-frailty to nationwide data from the Vascular Quality Initiative (VQI) (http:
//www.vascularqualityinitiative.org) on patients diagnosed with carotid artery dis-
ease (carotid stenosis). These data contain comprehensive information on all patients suffer-
ing from carotid stenosis and is continually updated over time to facilitate determination of
the best procedure or treatment approach to use on average and to determine which type of
patients benefit the most from each procedure. However, the data are exposed to a plethora
of selection biases raising concerns that naive analyses will yield biased results. Because the
outcomes of most interest are events such as stroke or death that can occur at any point
during follow-up, these data are ideal for application of the 2SRI-frailty procedure.
We employed 2SRI-F to estimate the comparative effectiveness of carotid endarterec-
tomy (CEA) versus carotid angioplasty and stenting (CAS), the two surgical procedures
used to intervene on patients with carotid stenosis. The data consist of 28712 patients who
received CEA and 8117 who received CAS, between 15 and 89 years of age, over 2003-2015.
During follow-up, there were 3955 and 807 deaths in the CEA and CAS groups, respectively.
Table 3 shows descriptive statistics for the measured covariates by procedure.
Figure 7 depicts two Kaplan-Meier survival curves: crude (left) and adjusted by patient
age, gender, ethnicity, race. type of surgery (elective/not elective), symptons (yes/no),
hypertension diabetes, smoking history (yes/no), positive stress test, coronary disease, heart
failure, diabetes, COPD, renal insufficiency, dialysis status (HD), prior ipsolateral CEA,
and the use of antiplatelet therapy, beta-blokers and statin by using the weighted inverse
propensity procedure MacKenzie et al. (2012). The crude hazard ratio (HR) comparing
CEA to CAS was 0.719 (95% CI of (0.666; 0.777)). Adjusted HR was 0.693 (0.633; 0.760).
The last HR is slightly modified when a frailty term is included: 0.685 (0.624; 0.753), and
0.676 (0.613; 0.745) for the Gaussian and Gamma cases, respectively.
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Table 3: Descriptive statistics for measured covariates both overall and by carotid en-
darterectomy (CES) versus carotid angioplasty and stenting (CAS) recipients.
CEA CAS
n=28,712 n=8,117
Age, mean±sd 70.2±9.4 69.1±10.3
Male, n (%) 17,180 (59.8) 5,119 (63.1)
Race, n (%)
White 27,033 (94.2) 7,382 (90.9)
Black 922 (3.2) 433 (5.3)
Other 757 (2.6) 302 (3.8)
Elective, n (%) 24,906 (86.7) 6,587 (81.1)
Symptomatic, n (%) 11,168 (38.9) 4,282 (52,7)
TIA or amaurosis, n (%) 6,405 (22.3) 2,001 (24.6)
Stroke, n (%) 4,763 (16.6) 2,281 (28.1)
Hypertension, n (%) 25,452 (88.6) 7,235 (89.1)
Smoking History, n (%) 22,098 (77.0) 6,168 (76.0)
Positive Stress Test, n (%) 2,655 (9.2) 677 (8.3)
Coronary Disease, n (%) 8,586 (29.9) 2,790 (34.4)
Heart Failure, n (%) 2,669 (9.3) 1,215 (15.0)
Diabetes, n (%) 9,749 (33.9) 2,942 (36.2)
COPD, n (%) 6,229 (21.7) 2,083 (25.7)
Renal Insufficiency, n (%) 1,649 (5.7) 446 (5.5)
HD, n (%) 263 (0.9) 114 (1.4)
Prior ipsilateral CEA, n (%) 4,472 (15.6) 2,857 (35.2)
Antiplatelet therapy, n (%)
Aspirin 23,960 (83.4) 6,932 (85.4)
P2y12 inhibitor 6,980 (24.3) 6,173 (76.0)
Beta-blocker, n (%) 18,269 (63.6) 4,602 (56.7)
Statin, n (%) 22,418 (78.1) 6,408 (78.9)
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As the instrumental variable we used the center level frequency of CEA versus CAS
procedures over the twelve months prior to the current patient; that is, total CEA divided
by total of CEA and CAS procedures in the twelve months prior to the current patient.
This variable is justified as an instrument due to: 1) hospitals that performed a high relative
amount of a certain procedure in the past are likely to keep doing so; 2) there should be no
effect of the relative frequency of CEA vs CAS on a patient’s outcome except through its
effect on treatment choice for that patient; 3) we know of no factors that would influence
both this frequency and a patient’s outcome. Reasons 2) and 3) are contingent on adjusting
for the total number of CEA and CAS procedures performed at the center over the past 12
months.
On the VQI data the IV is highly associated with treatment choice. The probability
that a randomly selected subject undergoing CEA has a larger value of the instrument
than a randomly selected subject undergoing CAS, was 0.881 (95% confidence interval of
(0.876; 0.885)). This IV was unrelated with all of the measured confounders suggesting
anecdotally that it may also be uncorrelated with any unmeasured confounders. Hence, it
is reasonable to assume that the relationship of the instrument with mortality is solely due
to its relationship with the treatment. Figure 8 (left side) shows the histogram of W in
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Figure 7: Kaplan-Meier estimations for both CEA and CAS group with 95% confidence
bands: crude (left) and adjusting by the covariates described in table 3 using the weighted
inverse propensity procedure (right).
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Table 4: Hazard ratios and 95% confidence intervals by estimation method.
HR (95% CI)
Crude 0.719 (0.666; 0.777)
Cox model (Naive) 0.693 (0.633; 0.760)
Naive - frailty (gaussian) 0.685 (0.624; 0.753)
Naive - frailty (gamma) 0.676 (0.613: 0.745)
2SRI 0.901 (0.737; 1.100)
2SRI - frailty (gaussian) 0.887 (0.724: 1.087)
2SRI - frailty (gamma) 0.882 (0.716; 1.086)
both CEA and CAS groups, at right, we show the boxplot for the IV by surgical procedure.
The treatment effect almost disappears when 2SRI is applied on the dataset: HR of 0.901
with a 95% confidence interval (0.737; 1.100). When the proposed 2SRI-frailty algorithm is
used a similar result obtains: a HR of 0.887 (βˆIVX = −0.120) with a 95% confidence interval
(0.724; 1.087). Similar results were also obtained under a gamma distributed frailty instead
of the gaussian frailty. Table 4 shows the hazard ratios and 95% confidence intervals.
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Figure 8: Histograms for the instrument variable (left), W , and boxplot (right), by received
treatment.
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5 Discussion
Instrumental variables methods are often used to account for unmeasured confounders.
Although these methods have been widely studied in a variety of situations, their suitability
for estimating Cox proportional hazard models is unclear. It is well-known that, in this case,
model misspecification can produce bias even when the omitted variables are unrelated with
the treatment assignment (Aalen et al., 2015); that is, when they only affect the survival
time. As suggested by our structural argument in the Introduction, an individual frailty
appears able to solve this problem. We showed that the presence of idiosyncratic variation
affecting treatment selection may induce a frailty in the instrumented survival time model
even if there is no frailty in the original survival model. In practice, the most likely scenario
is that both a true frailty and unmeasured confounding factors affect survival. For these
reasons, we were motivated to develop and evaluate an IV procedure that, in the second
stage, incorporates a frailty term.
Because the Cox model is nonlinear, our base strategy for dealing with unmeasured con-
founders was to use the two-stage residual inclusion algorithm, 2SRI, adapted to the Cox
model. As noted above, even when the true survival model does not contain omitted covari-
ates, the 2SRI procedure induces a frailty in the second-stage Cox regression model from
the inclusion of the residuals computed in the first stage. To account for this phenomenon,
we added an individual frailty in the second-stage (instrumented) statistical model. Under
standard reliability conditions, we proved the asymptotic consistency of the estimator de-
fined under our 2SRI-F procedure for the case when the univariate frailty distribution is
correctly assumed to be Gaussian.
Monte Carlo simulations suggested that the proposed methodology (2SRI-F) produces
an important bias reduction and is superior to the 2SRI, particularly in the presence of an
individual frailty due to unmeasured covariates unrelated with the treatment assignment. A
very important finding is that the bias of the 2SRI-F method was always close to zero even
when the residuals from the treatment selection equation were not normally distributed.
The Gaussian distribution can be directly justified when each individual frailty is the sum
of different independent sources of heterogeneity. Furthermore, because the procedure with
the Gaussian frailty was surprisingly robust to erroneously assumed frailty distributions,
we recommend using a Gaussian frailty.
A controversial feature of our procedure is the inclusion of the individual frailty term.
Although there exists a vast literature for the case where the frailty is common to a group
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of individuals (shared frailty), the number of references dealing with individual frailties is
minimal. Consistency properties of the common estimation algorithm for Cox models with
frailties were proved previously (Nielsen et al., 1992; Murphy, 1995). We adapted these
theoretical results in deriving the consistency results presented herein. By specifying a dis-
tribution for its values, the individual frailty accounts for the omitted covariates unrelated
with the treatment assignment – the extra variability introduced in the survival model
from the first stage of the algorithm () and the portion of V independent of U , freeing the
augmented first-stage residual (the control function) to deal with unmeasured confounding.
The resulting procedure estimates the average treatment effect conditional on the unmea-
sured confounder and the frailty (Yashin et al., 2001). Because in practice specification of
the distribution of the frailty can be arbitrary, the observed results should be handled with
caution (Hougaard, 1995) and they should be supported by sensitivity analyses considering
different frailty distributions. In the VQI application, the empirical results were found to
only have a slight dependence on the distribution of the frailty (see Figure 5). This is a key
finding that justifies the use of the 2SRI-F procedure and represents a major advance in the
instrumental variables literature for the analysis of time-to-event outcomes in observational
settings.
In the real-world application, a small but significant (at the 0.05 level) effect of the treat-
ment is detected when the presence of omitted covariates on the Cox model is ignored. This
effect almost disappears under 2SRI. When the 2SRI-F method is used, the estimated effect
of CEA over CAS is slightly larger. This result confirms that the effect of the procedure a
patient receives is underestimated when unmeasured confounding is ignored (Chamberlain,
1985; Gail et al., 1984). It is worth noting that different patient enrollment rates were ob-
served by treatment: while CAS patient censorship is constant across the follow-up, most
of the CEA patients have follow-up above two years with an important number censored
between the second and the fourth years. To the extent these differences are caused by an
unmeasured confounder, this can introduce additional bias in the standard naive estimates
and strongly motivates the use of an adequate instrumental variable procedure.
The method we developed conditions on all omitted covariates and assumes they have
multiplicative effects on the hazard function under the Cox model, unlike recently developed
methods that make unusual additive hazard assumptions in order to more simply account
for unmeasured confounding (MacKenzie et al., 2014; Tchetgen Tchetgen et al., 2015).
Therefore, we anticipate that our proposed and proven procedure will hold extensive appeal
and be widely used in practice.
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While it is encouraging that our null results cohere with those of recent RCTs (Rosenfield
et al., 2016; Brott et al., 2016), thereby overcoming the unfavorable CAS results of the non-
IV analyses, an effect close to 0 makes it difficult to distinguish our proposed IV procedure
from the incumbent two-stage residual inclusion method. However, when the true effect
is 0 (HR of 1), the bias from ignoring the frailty is 0 due to the fact that omitting a
frailty shrinks the true coefficient towards 0. Therefore, the differences between the 2SRI-
F and standard 2SRI procedure for the Cox model are expected to converge to 0 as the
true treatment effect approaches 0. In this sense, the lack of extensive differences between
the various 2SRI (frailty and standard) procedures is a real-data endorsement that our
proposed 2SRI-F procedure for the Cox model performs as it should by not rejecting the
null hypothesis when the RCT results and the 2SRI results suggest that the true effect is
close to 0.
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